{"filing":{"accession_number":"0001140361-26-033738","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"ef20080494_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126033738/ef20080494_8k.htm"},"events":[{"id":28487,"run_id":26062,"accession_number":"0001140361-26-033738","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"summary":"The filing discloses material shareholder litigation challenging the Merger Agreement and proxy disclosures. Three complaints were filed on August 6 and August 17, 2026 (McDaniels, Clark, and Drulias) alleging materially false and misleading statements in the proxy statement and seeking injunctive relief to prevent the merger or damages. Additionally, Crinetics received multiple demand letters from shareholders requesting corrective disclosures. While the company denies the allegations, the disclosure of pending litigation that could enjoin a $10 billion merger transaction is material to investors evaluating the merger.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30445,"accession_number":"0001140361-26-033738","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses material shareholder litigation challenging the Merger Agreement and proxy disclosures. Three complaints were filed on August 6 and August 17, 2026 (McDaniels, Clark, and Drulias) alleging materially false and misleading statements in the proxy statement and seeking injunctive relief to prevent the merger or damages. Additionally, Crinetics received multiple demand letters from shareholders requesting corrective disclosures. While the company denies the allegations, the disclosure of pending litigation that could enjoin a $10 billion merger transaction is material to investors evaluating the merger.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:05:15.789584+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30445,"accession_number":"0001140361-26-033738","item_number":"8.01","item_title":null,"event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses material shareholder litigation challenging the Merger Agreement and proxy disclosures. Three complaints were filed on August 6 and August 17, 2026 (McDaniels, Clark, and Drulias) alleging materially false and misleading statements in the proxy statement and seeking injunctive relief to prevent the merger or damages. Additionally, Crinetics received multiple demand letters from shareholders requesting corrective disclosures. While the company denies the allegations, the disclosure of pending litigation that could enjoin a $10 billion merger transaction is material to investors evaluating the merger.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:05:15.789584+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-19"}]}